Summary of the most appropriate alternative therapeutic options based on the BCR-ABL KD mutation status
| T315I |
| HSCT or investigational drugs |
| V299L, T315A, and F317L/V/I/C |
| Consider nilotinib rather than dasatinib |
| Y253H, E255K/V, and F359V/C/I |
| Consider dasatinib rather than nilotinib |
| Any other mutation |
| Consider high-dose imatinib* or dasatinib or nilotinib |
| T315I |
| HSCT or investigational drugs |
| V299L, T315A, and F317L/V/I/C |
| Consider nilotinib rather than dasatinib |
| Y253H, E255K/V, and F359V/C/I |
| Consider dasatinib rather than nilotinib |
| Any other mutation |
| Consider high-dose imatinib* or dasatinib or nilotinib |
HSCT indicates hematopoietic stem cell transplantation.
No sufficient data on dose escalation available to indicate if mutations with lower IC50 values are sensitive to high-dose imatinib.